22 May 2013
Keywords: indevus, licenses, european, sanctura, xr, rights, madaus
Article | 13 November 2006
The USA's Indevus Pharmaceuticals has licensed the rights to sell Sanctura XR (trospium Cl), the once-daily formulation of its
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 July 2006
21 May 2013
© 2013 thepharmaletter.com